Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 71Terminated 34Recruiting 31Active not recruiting 24Unknown 23Not yet recruiting 8Withdrawn 5Suspended 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Neoplasm Metastasis 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Resectable Pancreatic Cancer 1Recurrent Bladder Urothelial Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

Gemcitabine 27Taxes 9Capecitabine 8Albumin-Bound Paclitaxel 6pembrolizumab 5Radiosurgery 5Oxaliplatin 5Bevacizumab 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Specimen Handling 4Secretin 4Fluorouracil 4Drug Therapy 4Ascorbic Acid 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Cyclophosphamide 3Cisplatin 3Biopsy 3palbociclib 2methylnaltrexone 2folfirinox 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT06592664 2025-06-06

FORTIFIDE

Lisata Therapeutics, Inc.

Phase 1/2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

OHSU Knight Cancer Institute

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02048943 2015-01-09

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Roswell Park Cancer Institute

Phase 1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡